Meeting
2015 Gastrointestinal Cancers Symposium
The value of tissue protein expression as a predictor of efficacy for first or second-line therapy (tx) in metastatic ductal pancreas cancer (PDAC) in patients (pts) receiving either gemcitabine (G)-based tx or 5FU (F)-based tx.
Authors
Lauren Carcas
Florida Cancer Care, Boca Raton, FL
Lauren Carcas , Jessica Macintyre , Jaime R. Merchan , Peter Joel Hosein , Ikechukwu Immanuel Akunyili , Maria Restrepo , Monica T. Garcia , Lorraine Portelance , Danny Sleeman , Joe U Levi , Caio Max S. Rocha Lima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 460)
DOI
10.1200/jco.2015.33.3_suppl.460
Abstract #
460
Poster Bd #
E27
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Effectiveness and tolerability of maintenance capecitabine administrated to patients with metastatic pancreatic cancer treated with first line FOLFIRINOX.
First Author: Juliette Reure
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
First Author: Ivan Barrera